Published in Eur Arch Psychiatry Clin Neurosci on October 02, 2013
A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev (2016) 0.87
Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients. Eur Arch Psychiatry Clin Neurosci (2014) 0.81
Animal models of gene-environment interaction in schizophrenia: A dimensional perspective. Prog Neurobiol (2015) 0.79
Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci (2015) 0.77
Selected topics of the DGPPN Congress 2012. Eur Arch Psychiatry Clin Neurosci (2013) 0.75
CPA Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. Can J Psychiatry (2017) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA (1990) 17.70
The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry (1976) 15.48
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 11.27
Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry (2008) 3.29
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (2004) 2.93
Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry (1995) 2.73
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol (2001) 2.12
Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry (1994) 2.06
Cannabis, the mind and society: the hash realities. Nat Rev Neurosci (2007) 1.99
Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry (2012) 1.91
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Positive and negative symptoms in families with schizophrenia. Schizophr Res (1993) 1.74
The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) (2006) 1.72
Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry (1994) 1.72
Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev (2012) 1.60
Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry (1998) 1.57
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience (2001) 1.57
Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophr Res (2006) 1.36
The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull (2010) 1.32
Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry (2008) 1.30
Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist (2011) 1.27
Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. Schizophr Bull (2009) 1.26
Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull (1997) 1.26
Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance imaging analysis. Arch Neurol (1998) 1.25
A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophr Res (2011) 1.24
Meta-analysis of corpus callosum size in schizophrenia. J Neurol Neurosurg Psychiatry (1995) 1.21
Meta-analysis of magnetic resonance imaging studies of the corpus callosum in schizophrenia. Schizophr Res (2008) 1.20
Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res (2005) 1.15
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology (2000) 1.14
Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res (2007) 1.11
Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry (2010) 1.11
Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addict Behav (1999) 1.10
Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry (2007) 1.09
Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend (2010) 1.08
Cannabis use and brain structural alterations in first episode schizophrenia--a region of interest, voxel based morphometric study. Schizophr Res (2008) 1.07
Precipitation and determination of the onset and course of schizophrenia by substance abuse--a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res (2002) 1.06
Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res (1996) 1.06
Shape differences in the corpus callosum in first-episode schizophrenia and first-episode psychotic affective disorder. Am J Psychiatry (2002) 1.04
Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci (2010) 1.03
A selective review of volumetric and morphometric imaging in schizophrenia. Curr Top Behav Neurosci (2010) 1.02
Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia. Schizophr Res (2010) 1.01
Cannabis and schizophrenia. Cochrane Database Syst Rev (2008) 0.99
Schizophrenia, alcohol abuse, and violent behavior: a 26-year followup study of an unselected birth cohort. Schizophr Bull (1998) 0.99
Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci (1993) 0.99
The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry (2008) 0.95
Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur Neuropsychopharmacol (2002) 0.95
Callosal misconnectivity and the sex difference in psychosis. Int Rev Psychiatry (2007) 0.94
Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment. Psychol Med (2008) 0.93
Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry (2007) 0.93
Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry (2001) 0.92
Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry (1990) 0.92
A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl (1999) 0.92
Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J Clin Psychopharmacol (2011) 0.89
Corpus callosum size in schizophrenia--a magnetic resonance imaging analysis. Eur Arch Psychiatry Clin Neurosci (1999) 0.88
Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J Am Acad Child Adolesc Psychiatry (2011) 0.88
Hippocampal integrity and neurocognition in first-episode schizophrenia: a multidimensional study. World J Biol Psychiatry (2011) 0.88
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci (2012) 0.88
Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci (2009) 0.87
Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry (2011) 0.86
Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci (2006) 0.86
Corpus callosum size and shape in first-episode affective and schizophrenia-spectrum psychosis. Psychiatry Res (2009) 0.85
Gender differences in corpus callosum size in first-episode schizophrenics. Biol Psychiatry (1994) 0.84
Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res (2004) 0.84
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res (2013) 0.83
Anatomical MRI findings in mood and anxiety disorders. Epidemiol Psichiatr Soc (2002) 0.83
Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharm Des (2012) 0.81
[Biometric analysis of fresh volumes of various prosencephalic brain regions in 78 human adult brains]. Gegenbaurs Morphol Jahrb (1972) 0.81
Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis (1993) 0.81
Alcohol and cannabis use in Urban, African American, first-episode schizophrenia-spectrum patients: associations with positive and negative symptoms. J Clin Psychiatry (2007) 0.81
Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls. Eur Psychiatry (2011) 0.80
Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res (2010) 0.80
Anatomical characteristics of the corpus callosum and clinical correlates in schizophrenia. Eur Arch Psychiatry Clin Neurosci (1994) 0.79
Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings. Eur Arch Psychiatry Clin Neurosci (2013) 0.75
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry (2010) 3.42
Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry (2005) 2.84
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. Neuroimage (2011) 2.02
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
The role of interneuron networks in driving human motor cortical plasticity. Cereb Cortex (2012) 1.89
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
When desire collides with reason: functional interactions between anteroventral prefrontal cortex and nucleus accumbens underlie the human ability to resist impulsive desires. J Neurosci (2010) 1.68
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. Eur Arch Psychiatry Clin Neurosci (2008) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Functional architecture of verbal and tonal working memory: an FMRI study. Hum Brain Mapp (2009) 1.47
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
Protective drugs in acute large-dose exposure to organophosphates: a comparison of metoclopramide and tiapride with pralidoxime in rats. Anesth Analg (2005) 1.45
The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia (2012) 1.44
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol (2005) 1.39
[The confused patient]. MMW Fortschr Med (2014) 1.38
Diffuse axonal injury associated with chronic traumatic brain injury: evidence from T2*-weighted gradient-echo imaging at 3 T. AJNR Am J Neuroradiol (2003) 1.37
Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol (2007) 1.36
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull (2003) 1.34
Effects of antipsychotics on brain structure. Curr Opin Psychiatry (2006) 1.33
Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev (2008) 1.25
Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients. Am J Psychiatry (2004) 1.24
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna) (2009) 1.22
Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur Neuropsychopharmacol (2011) 1.21
Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study. Schizophr Res (2006) 1.21
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry (2007) 1.19
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex (2002) 1.18
Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci (2011) 1.18
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry (2010) 1.17
Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res (2009) 1.16
Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord (2005) 1.12
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry (2005) 1.11
The effects of physical exercise in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.11
Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies. Bipolar Disord (2012) 1.11
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry (2010) 1.10
Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients. Eur Arch Psychiatry Clin Neurosci (2014) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Neural substrates of olfactory processing in schizophrenia patients and their healthy relatives. Psychiatry Res (2007) 1.09
Automated MR image classification in temporal lobe epilepsy. Neuroimage (2011) 1.08
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One (2013) 1.06
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res (2010) 1.06
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol (2008) 1.05
Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y Acad Sci (2007) 1.05
Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev (2010) 1.04
Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry (2009) 1.04
Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res (2011) 1.04
Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur Arch Psychiatry Clin Neurosci (2011) 1.04
Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg (2007) 1.03
The neural substrate of the ideomotor principle: an event-related fMRI analysis. Neuroimage (2007) 1.03
Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr Res (2003) 1.03
Evaluation of cognition, structural, and functional MRI in juvenile myoclonic epilepsy. Epilepsia (2009) 1.02
Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun (2012) 1.01